SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMcbride Regulatory News (MCB)

Share Price Information for Mcbride (MCB)

Share Price is delayed by 15 minutes
Get Live Data
141.60    -24.20 (-14.60%)
Bid:
140.20
Ask:
144.80
Spread: 4.60 (3.281%)
Market Cap: £241.94m
MCB Live PriceLast checked at - London Stock Exchange

Intraday Mcbride Share Chart

Refinancing on improved terms

27 Jun 2017 07:00

RNS Number : 2177J
McBride PLC
27 June 2017
 

27 June 2017

 

McBride plc

 

Refinancing on improved terms

 

McBride plc ("the Group"), the leading European manufacturer and supplier of Co-manufactured and Private Label products for the Household and Personal Care market, today announces the refinancing of the Group in further support of the Group's Repair, Prepare, Grow strategy.

 

The Group has secured replacement banking facilities from a panel of international banks and using these increased facilities will repay its US Private Placement Notes ("USPP"). These actions will lower the cost of the Group's debt financing from the financial year starting on 1 July 2017 by approximately £2.0m per year.

 

 

Replacement Bank Facilities

 

The existing EUR 140m multi-currency revolving credit facility ("RCF") has been increased to a five year EUR 175m facility with a maturity of June 2022.

 

Features of the replacement facilities include:

 

- a EUR 175m RCF of which approximately EUR 70m will be drawn, providing the Group with significant committed funding headroom

- a 5 bps reduction in both margin and non-utilisation fees

- the addition of further borrowing entities and currencies, increasing flexibility going forward

- a EUR 75m uncommitted accordion feature will provide additional facilities for potential future acquisitions in support of the Grow phase of our strategy

 

The bank facilities are provided by a syndicate of HSBC, KBC, Bayern LB, BNP Paribas and Barclays.

 

US Private Placement Notes

 

The existing $50m 5.51%1 2020 USPP and $40m 5.38%1 2022 USPP will be repaid in full by drawing on the increased RCF.

 

Under the terms of the USPP arrangements, the Group will pay a 'make-whole' payment to existing USPP note-holders of approximately £11m2. At the same time the Group will close out the Euro/Dollar cross-currency interest rate swaps relating to the existing USPP notes which have a current mark-to-market net value of approximately £11m3 in favour of the Group.

 

Financing charges

 

Based on the current level of borrowings and interest swap rates, and taking into consideration the amortisation of initial fees, the Group's pro forma annual underlying finance charge will, over a full year, reduce by approximately £2m4 per annum. The Group's overall ongoing average cost of debt, after the repayment of the USPP, will reduce by approximately 310bps 4 to 150bps.

 

The 'make whole' payment to USPP note-holders will be treated for the Group's financial statements for the 12 months to 30 June 2017 as an exceptional finance charge. The total exceptional finance charge associated with this transaction will be approximately £13m comprising the make whole payment and additional USPP closure costs.

 

Net Debt

 

Following completion of all the transactions surrounding this change, which are expected by 30 June 2017, the impact on the Group's current net debt level will remain broadly unaffected.

 

 

Chris Smith, Chief Financial Officer of McBride, commented:

 

"As we prepare for the Grow phase of our strategy, we have secured an improvement in the cost, flexibility and duration of our banking facilities. The completion of this exercise represents another important milestone in the delivery of Repair, Prepare and Grow and reflects the strong ongoing support from our chosen banks."

 

 

Notes

1 - Adjusted for the impact of cross currency swap agreements.

2 - Will be treated as exceptional finance costs. Value estimated as at 23 June 2017.

3 - Will be treated as a movement on the derivative already reported in our income statement. Value estimated as at 23 June 2017.

4 - As compared to the position at 30 June 2016

 

 

For further information please contact:

 

McBride plc

Chris Smith, Chief Financial Officer

0161 203 7570

FTI Consulting

Ed Bridges, Nick Hasell

020 3727 1017

 

Note: This announcement contains inside information which is disclosed in accordance with the Market Abuse Regulation which came into effect on 3 July 2016.

 

-Ends-

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFFMPTMBITBIR
Date   Source Headline
1st Sep 20208:13 amRNSHolding(s) in Company
19th Aug 20207:00 amRNSHolding(s) in Company
14th Jul 20207:00 amRNSTrading update
26th Jun 20207:00 amRNSRedemption of B Shares
11th Jun 20207:00 amRNSDirectorate Change
19th May 20207:00 amRNSTrading Update
13th May 20204:35 pmRNSHolding(s) in Company
5th May 20205:00 pmRNSRedemption of B Shares
1st May 20207:00 amRNSChange in Remuneration Committee Responsibilities
28th Apr 20205:05 pmRNSDirector/PDMR Shareholding
25th Mar 20207:00 amRNSCOVID-19 Update
27th Feb 20205:00 pmRNSDirector/PDMR Shareholding
20th Feb 20207:00 amRNSHalf-year Report
16th Jan 20204:39 pmRNSHolding(s) in Company
14th Jan 20207:00 amRNSTrading Update
2nd Dec 20193:16 pmRNSIssue of B Shares as Part of the B Share Scheme
14th Nov 20197:00 amRNSDirectorate Change
6th Nov 20199:32 amRNSDirector/PDMR Shareholding
4th Nov 20194:00 pmRNSDirector/PDMR Shareholding
25th Oct 20193:57 pmRNSDirector/PDMR Shareholding
23rd Oct 20194:49 pmRNSResult of AGM
22nd Oct 20197:00 amRNSAGM Trading Update
15th Oct 20195:01 pmRNSTR1 Notification of major share holdings
8th Oct 20195:12 pmRNSDirector/PDMR Shareholding
8th Oct 20194:04 pmRNSDirector/PDMR Shareholding
8th Oct 20192:54 pmRNSDirector/PDMR Shareholding
7th Oct 20197:00 amRNSAppointment of Chairman Elect
4th Oct 20194:30 pmRNSHolding(s) in Company
4th Oct 20194:30 pmRNSDirector/PDMR Shareholding
4th Oct 20192:05 pmRNSAppointment of CEO and Chairman Succession
30th Sep 20194:12 pmRNSHolding(s) in Company
30th Sep 20194:05 pmRNSHolding(s) in Company
20th Sep 20194:00 pmRNSAnnual Report & Accounts & Notice of AGM
20th Sep 20194:00 pmRNSTotal Voting Rights
12th Sep 201911:06 amRNSDirector/PDMR Shareholding
5th Sep 20197:00 amRNSFinal Results
17th Jul 20193:18 pmRNSHolding(s) in Company
16th Jul 20194:25 pmRNSHolding(s) in Company
11th Jul 20197:00 amRNSTrading Update
26th Jun 20197:00 amRNSDirectorate Change
3rd Jun 20194:30 pmRNSIssue of B Shares as Part of the B Share Scheme
3rd Jun 20197:00 amRNSDirectorate Change
2nd May 20197:00 amRNSDirectorate Change and Trading Update
5th Apr 20192:23 pmRNSDirector/PDMR Shareholding
25th Mar 20194:38 pmRNSDirector Declaration
22nd Feb 201910:14 amRNSHolding(s) in Company
21st Feb 20197:00 amRNSHalf-year Report
20th Feb 20197:00 amRNSTrading Update
10th Jan 20197:00 amRNSTrading Update
4th Dec 20183:26 pmRNSIssue of B Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.